Cargando…
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction
AIMS: Sacubitril/valsartan combines renin–angiotensin–aldosterone system inhibition with amplification of natriuretic peptides. In addition to well‐described effects, natriuretic peptides exert direct effects on pulmonary vasculature. The effect of sacubitril/valsartan on pulmonary artery pressure (...
Autores principales: | Tran, Jeffrey S., Havakuk, Ofer, McLeod, Jennifer M., Hwang, Jennifer, Kwong, Hoi Yan, Shavelle, David, Zile, Michael R., Elkayam, Uri, Fong, Michael W., Grazette, Luanda P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006690/ https://www.ncbi.nlm.nih.gov/pubmed/33522140 http://dx.doi.org/10.1002/ehf2.13225 |
Ejemplares similares
-
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019) -
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018) -
Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021) -
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M, et al.
Publicado: (2021) -
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
por: Liu, Rex C.
Publicado: (2018)